Skip to main content
Erschienen in: Supportive Care in Cancer 5/2010

01.05.2010 | Original Article

Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients

verfasst von: Camilla Zimmermann, Debika Burman, Shazeen Bandukwala, Dori Seccareccia, Ebru Kaya, John Bryson, Gary Rodin, Christopher Lo

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Performance status (PS) scales are used widely in oncology practice and research. We compared inter-rater agreement, between nurses and physicians, for three commonly used PS scales.

Materials and methods

Patients attending an oncology palliative care clinic were assessed by a physician and nurse who blindly completed Eastern Cooperative Oncology Group (ECOG), Karnofsky PS (KPS), and palliative PS (PPS) scales. Patients completed the Edmonton symptom assessment system (ESAS).

Results

Inter-rater agreement (weighted kappa) for the 457 patients was 0.67 for the ECOG, 0.74 for the KPS, and 0.72 for the PPS. There was no difference between proportions of physicians’ vs. nurses’ ratings of KPS, >60 vs. ≤60 (McNemar’s test, p = 0.33); however, physicians were more likely to rate patients as having better PS for the ECOG (77% in the 0–2 range vs. 70% for nurses, p = 0.0003) and PPS (63% in the 70–100 range vs. 54% for nurses, p = 0.0001). Physician and nurse scores of ECOG, KPS, and PPS were all correlated with ESAS distress score (Pearson correlation, r = 0.4–0.5).

Conclusions

Although inter-rater agreement was good for all three scales, physicians tended to rate patients as healthier for the PPS and ECOG. The KPS may provide greater consistency of PS ratings by different oncology professionals in clinical and research settings.
Literatur
1.
Zurück zum Zitat Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11PubMed Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11PubMed
2.
Zurück zum Zitat Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85:1634–1639CrossRefPubMed Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85:1634–1639CrossRefPubMed
3.
Zurück zum Zitat Armitage P, Berry G, Matthews J (2002) Statistical methods in medical research. Blackwell, OxfordCrossRef Armitage P, Berry G, Matthews J (2002) Statistical methods in medical research. Blackwell, OxfordCrossRef
4.
Zurück zum Zitat Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151–156CrossRefPubMed Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151–156CrossRefPubMed
5.
Zurück zum Zitat Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
6.
Zurück zum Zitat Campos S, Zhang L, Sinclair E, Tsao M, Barnes EA, Danjoux C, Sahgal A, Goh P, Culleton S, Mitera G, Chow E (2009) The palliative performance scale: examining its inter-rater reliability in an outpatient palliative radiation oncology clinic. Support Care Cancer 17:685–690CrossRefPubMed Campos S, Zhang L, Sinclair E, Tsao M, Barnes EA, Danjoux C, Sahgal A, Goh P, Culleton S, Mitera G, Chow E (2009) The palliative performance scale: examining its inter-rater reliability in an outpatient palliative radiation oncology clinic. Support Care Cancer 17:685–690CrossRefPubMed
7.
Zurück zum Zitat Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L, MacRae JH, Martin M, Pelletier G, Robinson J, Simpson JS, Speca M, Tillotson L, Bultz BD (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90:2297–2304PubMed Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L, MacRae JH, Martin M, Pelletier G, Robinson J, Simpson JS, Speca M, Tillotson L, Bultz BD (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90:2297–2304PubMed
8.
Zurück zum Zitat Casarett DJ, Fishman JM, Lu HL, O’Dwyer PJ, Barg FK, Naylor MD, Asch DA (2009) The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol 27:953–959CrossRefPubMed Casarett DJ, Fishman JM, Lu HL, O’Dwyer PJ, Barg FK, Naylor MD, Asch DA (2009) The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol 27:953–959CrossRefPubMed
9.
Zurück zum Zitat Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88:2164–2171CrossRefPubMed Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88:2164–2171CrossRefPubMed
10.
Zurück zum Zitat Cheung WY, Barmala N, Zarinehbaf S, Rodin G, Le LW, Zimmermann C (2009) The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage 37:297–304CrossRefPubMed Cheung WY, Barmala N, Zarinehbaf S, Rodin G, Le LW, Zimmermann C (2009) The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage 37:297–304CrossRefPubMed
11.
Zurück zum Zitat Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I (2008) Predictive model for survival in patients with advanced cancer. J Clin Oncol 26:5863–5869CrossRefPubMed Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I (2008) Predictive model for survival in patients with advanced cancer. J Clin Oncol 26:5863–5869CrossRefPubMed
12.
Zurück zum Zitat Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37–46CrossRef Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37–46CrossRef
13.
Zurück zum Zitat Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scale disagreement or partial credit. Psychol Bull 70:213–220CrossRefPubMed Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scale disagreement or partial credit. Psychol Bull 70:213–220CrossRefPubMed
14.
Zurück zum Zitat Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. Cancer 65:1864–1866CrossRefPubMed Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. Cancer 65:1864–1866CrossRefPubMed
15.
Zurück zum Zitat Currow DC, Eagar K, Aoun S, Fildes D, Yates P, Kristjanson LJ (2008) Is it feasible and desirable to collect voluntarily quality and outcome data nationally in palliative oncology care? J Clin Oncol 26:3853–3859CrossRefPubMed Currow DC, Eagar K, Aoun S, Fildes D, Yates P, Kristjanson LJ (2008) Is it feasible and desirable to collect voluntarily quality and outcome data nationally in palliative oncology care? J Clin Oncol 26:3853–3859CrossRefPubMed
16.
Zurück zum Zitat Davis E, Nicolas C, Waters E, Cook K, Gibbs L, Gosch A, Ravens-Sieberer U (2007) Parent-proxy and child self-reported health-related quality of life: using qualitative methods to explain the discordance. Qual Life Res 16:863–871CrossRef Davis E, Nicolas C, Waters E, Cook K, Gibbs L, Gosch A, Ravens-Sieberer U (2007) Parent-proxy and child self-reported health-related quality of life: using qualitative methods to explain the discordance. Qual Life Res 16:863–871CrossRef
17.
Zurück zum Zitat de Borja MT, Chow E, Bovett G, Davis L, Gillies C (2004) The correlation among patients and health care professionals in assessing functional status using the karnofsky and eastern cooperative oncology group performance status scales. Support Cancer Ther 2:59–63CrossRefPubMed de Borja MT, Chow E, Bovett G, Davis L, Gillies C (2004) The correlation among patients and health care professionals in assessing functional status using the karnofsky and eastern cooperative oncology group performance status scales. Support Cancer Ther 2:59–63CrossRefPubMed
18.
Zurück zum Zitat Downing M, Lau F, Lesperance M, Karlson N, Shaw J, Kuziemsky C, Bernard S, Hanson L, Olajide L, Head B, Ritchie C, Harrold J, Casarett D (2007) Meta-analysis of survival prediction with palliative performance scale. J Palliat Care 23:245–252PubMed Downing M, Lau F, Lesperance M, Karlson N, Shaw J, Kuziemsky C, Bernard S, Hanson L, Olajide L, Head B, Ritchie C, Harrold J, Casarett D (2007) Meta-analysis of survival prediction with palliative performance scale. J Palliat Care 23:245–252PubMed
19.
Zurück zum Zitat Fainsinger RL, Demoissac D, Cole J, Mead-Wood K, Lee E (2000) Home versus hospice inpatient care: discharge characteristics of palliative care patients in an acute care hospital. J Palliat Care 16:29–34PubMed Fainsinger RL, Demoissac D, Cole J, Mead-Wood K, Lee E (2000) Home versus hospice inpatient care: discharge characteristics of palliative care patients in an acute care hospital. J Palliat Care 16:29–34PubMed
20.
Zurück zum Zitat Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC Quality of Life Group, Brussels Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC Quality of Life Group, Brussels
21.
Zurück zum Zitat Fleiss JL, Levin BA, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley-Interscience, Hoboken Fleiss JL, Levin BA, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley-Interscience, Hoboken
22.
Zurück zum Zitat Follwell M, Burman D, Le LW, Wakimoto K, Seccareccia D, Bryson J, Rodin G, Zimmermann C (2009) Phase II study of an outpatient palliative care intervention in patients with metastatic cancer. J Clin Oncol 27:206–213CrossRefPubMed Follwell M, Burman D, Le LW, Wakimoto K, Seccareccia D, Bryson J, Rodin G, Zimmermann C (2009) Phase II study of an outpatient palliative care intervention in patients with metastatic cancer. J Clin Oncol 27:206–213CrossRefPubMed
23.
Zurück zum Zitat Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327:195CrossRefPubMed Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327:195CrossRefPubMed
24.
Zurück zum Zitat Harrold J, Rickerson E, Carroll JT, McGrath J, Morales K, Kapo J, Casarett D (2005) Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med 8:503–509CrossRefPubMed Harrold J, Rickerson E, Carroll JT, McGrath J, Morales K, Kapo J, Casarett D (2005) Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med 8:503–509CrossRefPubMed
25.
Zurück zum Zitat Head B, Ritchie CS, Smoot TM (2005) Prognostication in hospice care: can the palliative performance scale help? J Palliat Med 8:492–502CrossRefPubMed Head B, Ritchie CS, Smoot TM (2005) Prognostication in hospice care: can the palliative performance scale help? J Palliat Med 8:492–502CrossRefPubMed
26.
Zurück zum Zitat Ho F, Lau F, Downing MG, Lesperance M (2008) A reliability and validity study of the palliative performance scale. BMC PalliatCare 7:10CrossRef Ho F, Lau F, Downing MG, Lesperance M (2008) A reliability and validity study of the palliative performance scale. BMC PalliatCare 7:10CrossRef
27.
Zurück zum Zitat Husain AF, Stewart K, Arseneault R, Moineddin R, Cellarius V, Librach SL, Dudgeon D (2007) Women experience higher levels of fatigue than men at the end of life: a longitudinal home palliative care study. J Pain Symptom Manage 33:389–397CrossRefPubMed Husain AF, Stewart K, Arseneault R, Moineddin R, Cellarius V, Librach SL, Dudgeon D (2007) Women experience higher levels of fatigue than men at the end of life: a longitudinal home palliative care study. J Pain Symptom Manage 33:389–397CrossRefPubMed
28.
Zurück zum Zitat Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O’Brien S, Kut M, Ratain MJ (1994) Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965–1973CrossRefPubMed Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O’Brien S, Kut M, Ratain MJ (1994) Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965–1973CrossRefPubMed
29.
Zurück zum Zitat Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer 85:1478–1485CrossRefPubMed Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer 85:1478–1485CrossRefPubMed
30.
Zurück zum Zitat Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11–20CrossRefPubMed Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11–20CrossRefPubMed
31.
Zurück zum Zitat Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents in cancer. Columbia University Press, New York, pp 191–205 Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents in cancer. Columbia University Press, New York, pp 191–205
32.
Zurück zum Zitat KFL&A Palliative Care Integration Project (2003) Symptom management guidelines. Queen’s University, Kingston KFL&A Palliative Care Integration Project (2003) Symptom management guidelines. Queen’s University, Kingston
33.
Zurück zum Zitat Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C (2006) Use of palliative performance scale in end-of-life prognostication. J Palliat Med 9:1066–1075CrossRefPubMed Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C (2006) Use of palliative performance scale in end-of-life prognostication. J Palliat Med 9:1066–1075CrossRefPubMed
34.
Zurück zum Zitat Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB III, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA (2007) Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33–40CrossRefPubMed Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB III, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA (2007) Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33–40CrossRefPubMed
35.
Zurück zum Zitat Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed
36.
Zurück zum Zitat Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53:2002–2007CrossRefPubMed Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53:2002–2007CrossRefPubMed
37.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed
38.
Zurück zum Zitat Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A (2008) Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112:831–836CrossRefPubMed Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A (2008) Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112:831–836CrossRefPubMed
39.
Zurück zum Zitat Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S (2007) Validation of the palliative performance scale in the acute tertiary care hospital setting. J Palliat Med 10:111–117CrossRefPubMed Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S (2007) Validation of the palliative performance scale in the acute tertiary care hospital setting. J Palliat Med 10:111–117CrossRefPubMed
40.
Zurück zum Zitat Patel SH, Ajlouni M, Chapman R, Lu M, Movsas B, Kim JH (2007) A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2:831–837CrossRefPubMed Patel SH, Ajlouni M, Chapman R, Lu M, Movsas B, Kim JH (2007) A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2:831–837CrossRefPubMed
41.
Zurück zum Zitat Philip J, Smith WB, Craft P, Lickiss N (1998) Concurrent validity of the modified Edmonton symptom assessment system with the Rotterdam symptom checklist and the brief pain inventory. Support Care Cancer 6:539–541CrossRefPubMed Philip J, Smith WB, Craft P, Lickiss N (1998) Concurrent validity of the modified Edmonton symptom assessment system with the Rotterdam symptom checklist and the brief pain inventory. Support Care Cancer 6:539–541CrossRefPubMed
42.
Zurück zum Zitat Riechelmann RP, Krzyzanowska MK, O’carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15:1407–1412CrossRefPubMed Riechelmann RP, Krzyzanowska MK, O’carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15:1407–1412CrossRefPubMed
43.
Zurück zum Zitat Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M, Boschetti E, Milella G, Ballatori E, Tonato M (1991) Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 2:437–439PubMed Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M, Boschetti E, Milella G, Ballatori E, Tonato M (1991) Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 2:437–439PubMed
44.
Zurück zum Zitat Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2:187–193PubMed Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2:187–193PubMed
45.
Zurück zum Zitat Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998CrossRefPubMed Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998CrossRefPubMed
46.
Zurück zum Zitat Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335CrossRefPubMed Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335CrossRefPubMed
47.
Zurück zum Zitat Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79CrossRefPubMed Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79CrossRefPubMed
48.
Zurück zum Zitat Westerman MJ, The AM, Sprangers MA, Groen HJ, van der WG, Hak T (2007) Small-cell lung cancer patients are just ‘a little bit’ tired: response shift and self-presentation in the measurement of fatigue. Qual Life Res 16:853–861CrossRefPubMed Westerman MJ, The AM, Sprangers MA, Groen HJ, van der WG, Hak T (2007) Small-cell lung cancer patients are just ‘a little bit’ tired: response shift and self-presentation in the measurement of fatigue. Qual Life Res 16:853–861CrossRefPubMed
49.
Zurück zum Zitat Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224CrossRefPubMed Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224CrossRefPubMed
50.
Zurück zum Zitat Zimmermann C, Seccareccia D, Clarke A, Warr D, Rodin G (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987CrossRefPubMed Zimmermann C, Seccareccia D, Clarke A, Warr D, Rodin G (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987CrossRefPubMed
Metadaten
Titel
Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients
verfasst von
Camilla Zimmermann
Debika Burman
Shazeen Bandukwala
Dori Seccareccia
Ebru Kaya
John Bryson
Gary Rodin
Christopher Lo
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0700-9

Weitere Artikel der Ausgabe 5/2010

Supportive Care in Cancer 5/2010 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.